Gene · 9123
Papers3,520
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,520
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| UNC93B1 promotes pancreatic cancer progression through modulation of cGAS-STING signaling. | Front Immunol | 2026 | 41716413 | PubTator, text mining | PubMed |
| Metabolic reprogramming orchestrates an immunosuppressive microenvironment in anaplastic thyroid cancer: mechanisms and clinical perspectives. | Front Immunol | 2026 | 41716397 | PubTator, text mining | PubMed |
| Nanomedicine-based lactate metabolism and lactylation regulation for exploring new therapeutic strategies in cancer. | Mater Today Bio | 2026 | 41716334 | PubTator, text mining | PubMed |
| Lactylation in colorectal cancer: Unveiling novel mechanisms in metabolism, progression and therapeutic targeting. | Clin Transl Med | 2026 | 41711048 | PubTator, text mining | PubMed |
| Apoptosis and Metabolic Reprogramming by RHART in Hepatocellular Carcinoma Through the CPSF6/MCT4/c-Myc Signaling In Vitro and In Vivo. | Phytother Res | 2026 | 41708579 | PubTator, text mining | PubMed |
| Glycolysis enzymes and cellular lactylation in tumour. | Clin Transl Med | 2026 | 41705280 | PubTator, text mining | PubMed |
| Metabolic marker profiling of circulating tumour cells in NSCLC patients treated with osimertinib: focus on MCT1 and MCT4. | Ther Adv Med Oncol | 2026 | 41705139 | PubTator, text mining | PubMed |
| β-Catenin-Facilitated Glycolytic Reprogramming Fuels TNBC Progression: Therapeutic Blockade with XAV939. | Technol Cancer Res Treat | 2026 | 41700965 | PubTator, text mining | PubMed |
| Lactate metabolism-driven tumor heterogeneity and molecular signatures in intrahepatic cholangiocarcinoma. | World J Gastroenterol | 2026 | 41694488 | PubTator, text mining | PubMed |
| Metabolism in Tumour-Induced Bone Disease. | Curr Osteoporos Rep | 2026 | 41692878 | PubTator, text mining | PubMed |
| Genome-wide CRISPRi screen identifies basigin loss as protective in cardiac hypoxia. | bioRxiv | 2026 | 41659663 | PubTator, text mining | PubMed |
| Targeting ENO1 reprograms macrophage polarization to trigger antitumor immunity and improves the therapeutic effect of radiotherapy. | Cell Death Dis | 2026 | 41629269 | PubTator, text mining | PubMed |
| The moonlighting functions of glycolytic enzymes in tumorigenesis. | Cell Oncol (Dordr) | 2026 | 41627634 | PubTator, text mining | PubMed |
| Lactate transmission from hypoxic tumor cells promotes macrophage senescence and M2 polarization via the DNMT1-NHE7 axis to accelerate endometrial cancer progression. | Cell Death Dis | 2026 | 41617670 | PubTator, text mining | PubMed |
| SCFAs' pleiotropic role in pathogenesis and salutogenesis: mechanisms in exacerbation and regulation of inflammation and fibrosis from gut to host. | J Med Microbiol | 2026 | 41609721 | PubTator, text mining | PubMed |
| Metabolic Radiosensitization by Targeting Lactate Metabolism with Microfluidic Liposomal Nanocarriers. | ACS Biomater Sci Eng | 2026 | 41603671 | PubTator, text mining | PubMed |
| Lactate-lactylation in tumor angiogenesis and progression: mechanisms, biomarker potential, and therapeutic implications. | Biomark Res | 2026 | 41593811 | PubTator, text mining | PubMed |
| Resident CD49a+CD103+NKG2C+ NK cells restrict HIV infection in human lymphoid tissue explants. | Sci Adv | 2026 | 41576166 | PubTator, text mining | PubMed |
| Beyond metabolism: exploring the regulatory and therapeutic implications of lactate and lactylation in cancer-regulated cell death. | Cell Death Dis | 2026 | 41571623 | PubTator, text mining | PubMed |
| Heterogeneity of glucose metabolism and uptake identifies distinct cancer cell and cancer stem cell phenotypes. | Cell Mol Biol Lett | 2026 | 41547734 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9123/papers?page=6